Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side.
Journal Information
Full Title: CPT Pharmacometrics Syst Pharmacol
Abbreviation: CPT Pharmacometrics Syst Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"CONFLICT OF INTEREST STATEMENT The authors declared no competing interests for this work."
"FUNDING INFORMATION No funding was received for this work."
"The study protocol was approved by the regional research ethics Committee of the Canton of Geneva (CCER no. 2017‐00225). The OptimAT study aims to validate PBPK models for antithrombotic therapy and is registered in the US National Institutes of Health Clinical Trials Registry (NCT03477331). Written informed consent was obtained from all patients prior to initiation of any study procedure. This clinical trial was carried out in compliance with the principles of the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice Guidelines."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025